Esophageal Squamous Cell Carcinoma
Conditions
Brief summary
The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by esophagectomy. Researchers will review existing clinical, pathologic, and follow-up data from 414 patients treated at three medical centers between 2019 and 2025. The study will assess whether routinely available clinicopathologic factors can provide prognostic information beyond postoperative pathologic staging.
Interventions
None listed
Sponsors
Sichuan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Age 18 to 80 years Histologically confirmed esophageal squamous cell carcinoma Received at least 1 cycle of neoadjuvant chemoimmunotherapy before surgery Underwent subsequent esophagectomy
Exclusion criteria
History of other malignancies Preoperative antitumor therapy other than neoadjuvant chemoimmunotherapy Incomplete clinicopathologic or follow-up data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From the date of esophagectomy to death or last follow-up, up to 73 months. | Overall survival is defined as the interval from the date of esophagectomy to death from any cause. Participants alive at last contact are censored on the date of last follow-up. |
Countries
China
Outcome results
None listed